Cancer survival has improved substantively over time such that the majority of people diagnosed with cancer now survive long term. This necessitates holistic consideration of prevention and management of cardiovascular disease and other comorbidities in cancer survivors, alongside optimal management of cancer, to support lives that are as long and fulfilling as possible for those affected. Large-scale data have transformed cancer prevention, diagnosis and treatment and are likely to transform our understanding and optimisation of cancer survivorship. Cancer diagnosis and its treatment predispose to cardiovascular disease. Cardiovascular risk factors and disease are very common in the general population and may be neglected in the setting of cancer diagnosis. This presentation will outline a world-first large-scale general-population linked data platform for survivorship research, comprising >70,000 cancer survivors (including >20,000 developing cancer during follow up) and >190,000 people without cancer, participating in the Sax Institute’s 45 and Up Study. It will present preliminary data on cardiovascular risk and outcomes in participants with and without cancer, including according to cancer type, to inform prevention and management.